RENAsym, a quantitative systems toxicology platform model, designed to predict drug-induced kidney injury indicates polymyxin B and valproate overdose toxicity potential while simultaneously demonstrating acetaminophen and valproate safety at therapeutic levels
Toxicological Sciences · 2026
DOI: 10.1093/toxsci/kfag047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicological Sciences, 2026. Verfasst von Celeste Vallejo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Simulations Plus, Research Triangle Park, NC 27709, United States. Hauptthemen laut MEDLINE: Valproic Acid, Acetaminophen, Polymyxin B, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, Small Business Innovation Research.
Abstract (Originalsprache)
RENAsym is a quantitative systems toxicology (QST) modeling platform designed to predict drug-induced kidney toxicity. The model includes the proximal tubule cell (PTC) life cycle, regeneration of PTCs, sodium reabsorption, nephron death, and drug-induced injury and inflammation within the proximal tubules. The mechanisms of drug-induced toxicity included are overproduction of reactive oxygen species and mitochondrial dysfunction. Inputs into the QST model include the drug’s exposure in the kidney and results from in vitro toxicity assays used to parameterize the toxicity mechanisms included in the model. The QST model has a wide array of outputs including fraction of viable PTCs, fraction of viable nephrons, and serum creatinine concentration over time that allow the user to assess the extent of kidney injury induced by a drug. Polymyxin B, valproate, and acetaminophen were three compounds used to test RENAsym’s ability to correctly classify compounds as either nephrotoxic or safe. The model successfully identified polymyxin B and valproate as drugs with the potential to cause kidney injury and acetaminophen as a drug that does not cause kidney injury at therapeutic levels, providing increased confidence that the model can be used to indicate kidney injury liability using in vitro inputs before dosing in clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Simulations Plus, Research Triangle Park, NC 27709, United States.
ORCID-Profile: Lara Clemens
Förderung
- NIDDK NIH HHS
- Small Business Innovation Research
Zitieren
APA
Vallejo, C., Bhargava, P., Hamzavi, N., McDaniel, M., Lakhani, V. V., Qi, T., Battista, C., Clemens, L., Shoda, L. K. M., Kenz, Z. R., Tallapaka, S., Gebremichael, Y., & Woodhead, J. L. (2026). RENAsym, a quantitative systems toxicology platform model, designed to predict drug-induced kidney injury indicates polymyxin B and valproate overdose toxicity potential while simultaneously demonstrating acetaminophen and valproate safety at therapeutic levels. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfag047
Vancouver
Vallejo C, Bhargava P, Hamzavi N, McDaniel M, Lakhani VV, Qi T, et al. RENAsym, a quantitative systems toxicology platform model, designed to predict drug-induced kidney injury indicates polymyxin B and valproate overdose toxicity potential while simultaneously demonstrating acetaminophen and valproate safety at therapeutic levels. Toxicological Sciences. 2026. doi:10.1093/toxsci/kfag047
BibTeX
@article{Vallejo2026,
author = {Vallejo, Celeste and Bhargava, Pallavi and Hamzavi, Nader and McDaniel, Matthew and Lakhani, Vinal V and Qi, Timothy and Battista, Christina and Clemens, Lara and Shoda, Lisl K M and Kenz, Zackary R and Tallapaka, Shailendra and Gebremichael, Yeshitila and Woodhead, Jeffrey L},
title = {RENAsym, a quantitative systems toxicology platform model, designed to predict drug-induced kidney injury indicates polymyxin B and valproate overdose toxicity potential while simultaneously demonstrating acetaminophen and valproate safety at therapeutic levels},
journal = {Toxicological Sciences},
year = {2026},
doi = {10.1093/toxsci/kfag047}
}
EUVIMED